The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.
I have added this link for info purposes.
https://companieshouse.blog.gov.uk/2019/02/27/what-does-going-into-administration-mean/
Usually eight weeks from the appointment of the administrator, so we're looking at around the end of March.
Welcome back Freddieboy.
The same problem exists today that existed when you last left in that the company has a potential product in exosomes, but as yet it hasn't been realized.
There was an RNS on exosomes and proof of concept invitro and that the next stage of delivery of drugs to specific parts of a body in large enough quantities to be effective was going to begin.
There was going to be an announcement at a conference and then it suddenly all went quiet, and nobody knows why.
This where we all are now.
P.S, I think the company runs out of money in April. Good luck.
The BOD seems to be preparing people for the battle ahead which could go either way.
Here are some scenarios.
1) A miracle happens and POC is found by one of the companies currently doing the work. They've been at it for a year and there's been no feedback yet!
2) The BOD goes back to the market in Q1 or Q2 and the market conditions are more conducive and less risk adverse, but this is more hope than an actual plan.
3) We ask the Quatar, Saudi Arabia or any of the gulf rich states for the money, they've got plenty of it
4) We ask some dodgy oligarch for the money, but we might have to go to war with Ukraine or join the Wagner Group.
5) If none of the above are viable the company may be put into administration and sold as going concern, so you might get something back.
6) Worst case scenario, involuntary liquidation.
I would personally like to thank the previous board for sitting on exosomes for the past nine years, firing the guy who was in charge of the program, and wasting all the money raised on passion projects that had little chance of fruition.
I hope that they choke on their turkey and may the yule log's role from their fireplaces and burn their houses to the ground.
Merry Christmas everyone and a Happy New Year.
It's a shame but these things happen in pharmaceutical trials all the time. GSK had to stop a 3rd stage clinical trail due to problems. There is a POC data delivery of functional proteins by CTX derived exosome due in the next few weeks, so swings and roundabouts with this one.
Someone just brought 30,000 shares on the close.
The money burn is a concern, but if the phase 2 trail brings the results that we all believe it will then raising any money should be not be a problem, as they company has proven safety, efficacy and clear medical benefit. The final trial is there so Doctors can see if the new procedure or drug is better than what currently exists. The current prognosis for RP is blindness, so this will save peoples sight and give hope where there was none. That's got to be worth something to someone.
What I don't understand about this share is that it is in better position than it was five years ago, but it's price is a quarter of what it was. I smell the stench of a market manipulation. Manipulating stock prices can happen quite easily, and it takes place more often than you might think. Achieving it in a perfectly legal way is not necessarily difficult, depending on how much trading power an entity has. Manipulation takes many forms in the markets. One way people can deflate the price of a security is by placing hundreds of small orders at a significantly lower price than the one at which it has been trading. It is much easier to manipulate the share price of smaller companies, such as penny stocks, because they are not as closely watched by analysts and other market participants as the medium and large cap firms. Thoughts anyone?
Aviva no longer appear on the official Reneuron website as a stockholder. There have been a number of notifications of major share dealing over the last few days. Finally they are gone!
Lottery tickets anyone? �154,000,000, more chance of winning this than Reneuron getting a product to market in the next five years.
With the new office opening in Boston this might help speed up FDA approval.
As Cadbury Hill stated shorting a penny stock is either brave or suicidal, but when you look the chart for the last year that iswhat is seems to be happening. Woodford invested £35 million last July and since then the stock has sunk like the Titanic. Usually when someone puts that type of cash in the stock goes up, but any big buys are swamped by sells straight away thus keeping downward pressure on the SP. Why I can't explain but that's what happening.
I think that Olev said, in a recent interview, 2020 earliest or 2022 latest. The problem with this share is that the clinical trials have time slipped considerably. Phase 3 clinical trial should have been completed by now, but as you can see it hasn't even started yet. As you rightly stated until the company has a product and turnover it's going to be very difficult to generate intrest in it.